Metabolic Syndrome (MetS) is a complex epidemic disorder with an impact on both lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). Combination therapy of daily tadalafil and tamsulosin may provide relief to both diseases. Aim of the present study is to assess the impact of combination therapy of Tadalafil 5mg plus Tamsulosin 0.4mg on LUTS and ED, according to presence vs. absence of Mets.
75 Consecutive men presenting with ED and LUTS suggestive of bladder prostatic obstruction were enrolled. Patients were divided into two groups according to MetS presence or absence. All subjects were then treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5 and comparison were made in and between groups.
Study Type
OBSERVATIONAL
Enrollment
75
Combination therapy of daily tadalafil plus tamsulosin
Lower Urinary Tract Symptoms
Through IPSS
Time frame: Changes from Baseline IPSS at 3 months
Lower Urinary Tract Symptoms - Storage
Through OAB-q
Time frame: Changes from Baseline OAB-q at 3 months
Erectile Dysfunction
Through IIEF-5
Time frame: Changes from Baseline IIEF-5 at 3 months
Flowmetry Maximum Flow
Through Maximum Flow (ml/s)
Time frame: Changes from Baseline Maximum Flow at 3 months
Flowmetry Post Void Residual
Through Post Void Residual (ml)
Time frame: Changes from Baseline Post Void Residual at 3 months
Combination Therapy Adverse Events
Drug related adverse events were collected
Time frame: 3 months
Combination Therapy Compliance
Adherence to therapy - did all the patients took the combination therapy daily
Time frame: 3 months
Combination Therapy Tolerability
Measured by the study completion rate by the participants
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.